Skip to content

Denosumab

Prolia, Xgeva (denosumab) is an antibody pharmaceutical. Denosumab was first approved as Prolia on 2010-05-26. It is used to treat osteoporotic fractures and postmenopausal osteoporosis in the USA. It has been approved in Europe to treat bone fractures, bone resorption, neoplasm metastasis, and postmenopausal osteoporosis. The pharmaceutical is active against tumor necrosis factor ligand superfamily member 11.
Trade Name Prolia, Xgeva
Common Name Denosumab
Indication bone fractures, bone resorption, neoplasm metastasis, osteoporotic fractures, postmenopausal osteoporosis
Drug Class Monoclonal antibodies: fully human, bone target
Denosumab
Get full access now